A Multicenter, Multinational, Phase 3b, Open-Label Extension Trial to Assess the Safety and Tolerability of Long-Term Treatment of Rotigotine Patch in Subjects With Idiopathic Parkinson's Disease.

Trial Profile

A Multicenter, Multinational, Phase 3b, Open-Label Extension Trial to Assess the Safety and Tolerability of Long-Term Treatment of Rotigotine Patch in Subjects With Idiopathic Parkinson's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2015

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Schwarz Pharma AG; UCB
  • Most Recent Events

    • 20 Apr 2015 Post-hoc analysis of pooled data presented at the 67th Annual Meeting of the American Academy of Neurology (AAN), according to a UCB media release.
    • 16 Oct 2009 UCB, Inc. added as trial sponsor as reported by ClinicalTrials.gov.
    • 16 Oct 2009 Additional locations identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top